Estimating the Shares of the Value of Branded Pharmaceuticals Accruing to Manufacturers and to Patients in the Thai Healthcare System
Quantification of the lifecycle value of new pharmaceuticals can better inform policies that enhance population health. In Thailand, policies that could improve overall population health include earlier adoption of new pharmaceuticals alongside careful price regulation and expedited generic entry. These approaches could also provide mechanisms to signal research and development priorities effectively.
Authors
- Chotika Suwanpanich (ORCID: https://orcid.org/0009-0000-8944-6225)
- Jessica Ochalek (ORCID: https://orcid.org/0000-0003-0744-1178)
- Beth Woods (ORCID: https://orcid.org/0000-0002-7669-9415)
- James Lomas (ORCID: https://orcid.org/0000-0002-2478-7018)
- Yot Teerawattananon (ORCID: https://orcid.org/0000-0003-2217-2930)
- Budsadee Soboon
- Lapad Pongcharoenyong
- Francis Carlo Panlilio
Institutions
- University of York (GB)
Publication Details
- Journal
- Value in Health
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.jval.2025.10.004
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00